Literature DB >> 25644547

The response to ACTH is determined early in the treatment of infantile spasms.

John R Mytinger1, Amanda Weber1, Geoffrey L Heyer1.   

Abstract

Although adrenocorticotropic hormone is the most commonly used treatment for infantile spasms in the United States, the optimal regimen for this indication is not known. The purpose of this study was to elucidate the optimal adrenocorticotropic hormone treatment duration. We conducted a retrospective chart review of response to adrenocorticotropic hormone among all patients with infantile spasms managed at our institution from January 2009 to September 2013. Treatment response was defined as clinical remission for greater than or equal to 28 days starting at any point within the adrenocorticotropic hormone course and remission of hypsarrhythmia (or definite EEG improvement if hypsarrhythmia was absent at baseline). For responders, the diagnostic and post-treatment EEG tracings were reviewed. Electroclinical remission was achieved in 21 of 39 patients (54%) receiving adrenocorticotropic hormone, including 11/25 (44%) receiving a long course (typically 12 weeks) and 10/14 (71%) receiving a short course (typically four weeks). The mean time to clinical remission was 5.8 days (median: 5 days; range: 1-20 days). Only one patient responded beyond two weeks of treatment. This study provides Class IV evidence that among patients with infantile spasms, the response to adrenocorticotropic hormone is most often determined early in the treatment course. Given the importance of rapid remission, clinicians should consider adding or changing treatment if infantile spasms do not resolve within two weeks of adrenocorticotropic hormone initiation. Further study is needed to determine the optimal adrenocorticotropic hormone regimen for infantile spasms.

Entities:  

Keywords:  ACTH; West syndrome; adrenocorticotropic hormone; infantile spasms

Mesh:

Substances:

Year:  2015        PMID: 25644547     DOI: 10.1684/epd.2014.0723

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  5 in total

Review 1.  West Syndrome: A Review and Guide for Paediatricians.

Authors:  Renato D'Alonzo; Donato Rigante; Elisabetta Mencaroni; Susanna Esposito
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms.

Authors:  Jinghua Yin; Qianjin Lu; Fei Yin; Ying Wang; Fang He; Liwen Wu; Lifen Yang; Xiaolu Deng; Chen Chen; Jing Peng
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

3.  Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline.

Authors:  John R Mytinger; Dara V F Albert; Jaime D Twanow; Jorge Vidaurre; Yubo Tan; Guy N Brock; Adam P Ostendorf
Journal:  Pediatr Neurol       Date:  2019-12-03       Impact factor: 4.210

4.  Adrenal Function Testing Following Hormone Therapy for Infantile Spasms: Case Series and Review of Literature.

Authors:  John R Mytinger; Sasigarn A Bowden
Journal:  Front Neurol       Date:  2015-12-08       Impact factor: 4.003

5.  Management of Infantile Spasms During the COVID-19 Pandemic.

Authors:  Zachary M Grinspan; John R Mytinger; Fiona M Baumer; Michael A Ciliberto; Bruce H Cohen; Dennis J Dlugos; Chellamani Harini; Shaun A Hussain; Sucheta M Joshi; Cynthia G Keator; Kelly G Knupp; Patricia E McGoldrick; Katherine C Nickels; Jun T Park; Archana Pasupuleti; Anup D Patel; Asim M Shahid; Renee A Shellhaas; Daniel W Shrey; Rani K Singh; Steven M Wolf; Elissa G Yozawitz; Christopher J Yuskaitis; Jeff L Waugh; Phillip L Pearl
Journal:  J Child Neurol       Date:  2020-06-23       Impact factor: 1.987

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.